These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 15243931)

  • 1. Immunogenicity of pneumococcal vaccination of patients with cochlear implants.
    Rose M; Hey C; Kujumdshiev S; Gall V; Schubert R; Zielen S
    J Infect Dis; 2004 Aug; 190(3):551-7. PubMed ID: 15243931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does the 23-valent pneumococcal vaccine protect cochlear implant recipients?
    Hey C; Rose MA; Kujumdshiev S; Gstoettner W; Schubert R; Zielen S
    Laryngoscope; 2005 Sep; 115(9):1586-90. PubMed ID: 16148699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of the American Academy of Pediatrics--recommended sequential pneumococcal conjugate and polysaccharide vaccine schedule in pediatric solid organ transplant recipients.
    Lin PL; Michaels MG; Green M; Mazariegos GV; Webber SA; Lawrence KS; Iurlano K; Greenberg DP
    Pediatrics; 2005 Jul; 116(1):160-7. PubMed ID: 15995047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The 23-valent pneumococcal polysaccharide vaccine does not provide additional serotype antibody protection in children who have been primed with two doses of heptavalent pneumococcal conjugate vaccine.
    Balmer P; Borrow R; Arkwright PD
    Vaccine; 2007 Aug; 25(34):6321-5. PubMed ID: 17629373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunoglobulins and immunogenicity of pneumococcal vaccination in preschool asthma.
    Rose MA; Schubert R; Kujumdshiev S; Kitz R; Zielen S
    Int J Clin Pract; 2006 Nov; 60(11):1425-31. PubMed ID: 17073839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy.
    Abzug MJ; Pelton SI; Song LY; Fenton T; Levin MJ; Nachman SA; Borkowsky W; Rosenblatt HM; Marcinak JF; Dieudonne A; Abrams EJ; Pathak I;
    Pediatr Infect Dis J; 2006 Oct; 25(10):920-9. PubMed ID: 17006288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Total and serotype-specific pneumococcal antibody titres in children with normal and abnormal humoral immunity.
    Uddin S; Borrow R; Haeney MR; Moran A; Warrington R; Balmer P; Arkwright PD
    Vaccine; 2006 Jul; 24(27-28):5637-44. PubMed ID: 16730399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory.
    de Roux A; Schmöle-Thoma B; Siber GR; Hackell JG; Kuhnke A; Ahlers N; Baker SA; Razmpour A; Emini EA; Fernsten PD; Gruber WC; Lockhart S; Burkhardt O; Welte T; Lode HM
    Clin Infect Dis; 2008 Apr; 46(7):1015-23. PubMed ID: 18444818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomised revaccination with pneumococcal polysaccharide or conjugate vaccine in asplenic children previously vaccinated with polysaccharide vaccine.
    Smets F; Bourgois A; Vermylen C; Brichard B; Slacmuylders P; Leyman S; Sokal E
    Vaccine; 2007 Jul; 25(29):5278-82. PubMed ID: 17576024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.
    Wysocki J; Tejedor JC; Grunert D; Konior R; Garcia-Sicilia J; Knuf M; Bernard L; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S77-88. PubMed ID: 19325450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of sequential pneumococcal vaccination in subjects splenectomised for hereditary spherocytosis.
    Stoehr GA; Rose MA; Eber SW; Heidemann K; Schubert R; Zielen S
    Br J Haematol; 2006 Mar; 132(6):788-90. PubMed ID: 16487181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of a 2+1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway.
    Vestrheim DF; Løvoll O; Aaberge IS; Caugant DA; Høiby EA; Bakke H; Bergsaker MR
    Vaccine; 2008 Jun; 26(26):3277-81. PubMed ID: 18456376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent polysaccharide vaccine in adults aged 50-80 years.
    Goldblatt D; Southern J; Andrews N; Ashton L; Burbidge P; Woodgate S; Pebody R; Miller E
    Clin Infect Dis; 2009 Nov; 49(9):1318-25. PubMed ID: 19814624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV).
    Knuf M; Szenborn L; Moro M; Petit C; Bermal N; Bernard L; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S97-S108. PubMed ID: 19325452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of sequential pneumococcal immunization in preschool asthmatics.
    Rose MA; Gruendler M; Schubert R; Kitz R; Schulze J; Zielen S
    Vaccine; 2009 Aug; 27(38):5259-64. PubMed ID: 19576944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pneumococcal conjugate vaccination does not induce a persisting mucosal IgA response in children with recurrent acute otitis media.
    Bogaert D; Veenhoven RH; Ramdin R; Luijendijk IH; Rijkers GT; Sanders EA; de Groot R; Hermans PW
    Vaccine; 2005 Apr; 23(20):2607-13. PubMed ID: 15780443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of current joint American Academy of Allergy, Asthma & Immunology and American College of Allergy, Asthma and Immunology guidelines for antibody response to the 23-valent pneumococcal vaccine using a population of HIV-infected children.
    Kamchaisatian W; Wanwatsuntikul W; Sleasman JW; Tangsinmankong N
    J Allergy Clin Immunol; 2006 Dec; 118(6):1336-41. PubMed ID: 17157665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Type-specific antibodies to pneumococcal capsular polysaccharide acquired either naturally or after vaccination with Prevenar in children with underlying chronic or recurrent lung diseases.
    Navarro D; Escribano A; Cebrián L; Gimeno C; García-Maset L; García-de-Lomas J;
    Clin Vaccine Immunol; 2006 Jun; 13(6):665-70. PubMed ID: 16760325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and safety of measles-mumps-rubella, varicella and Haemophilus influenzae type b vaccines administered concurrently with a fourth dose of heptavalent pneumococcal conjugate vaccine compared with the vaccines administered without heptavalent pneumococcal conjugate vaccine.
    Black SB; Cimino CO; Hansen J; Lewis E; Ray P; Corsaro B; Graepel J; Laufer D
    Pediatr Infect Dis J; 2006 Apr; 25(4):306-11. PubMed ID: 16567981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Administration of protein-conjugate pneumococcal vaccine to patients who have invasive disease after splenectomy despite their having received 23-valent pneumococcal polysaccharide vaccine.
    Musher DM; Ceasar H; Kojic EM; Musher BL; Gathe JC; Romero-Steiner S; White AC
    J Infect Dis; 2005 Apr; 191(7):1063-7. PubMed ID: 15747240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.